Find Procarbazine Hydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

VMF

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

0

South Africa

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

59RELATED EXCIPIENT COMPANIES

115EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

GLOBAL SALES INFORMATION

Annual Reports

NA

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 366-70-1, Procarbazine hcl, Matulane, Nathulane, Natunalar, Natulan
Molecular Formula
C12H20ClN3O
Molecular Weight
257.76  g/mol
InChI Key
DERJYEZSLHIUKF-UHFFFAOYSA-N
FDA UNII
XH0NPH5ZX8

Procarbazine Hydrochloride
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
1 2D Structure

Procarbazine Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide;hydrochloride
2.1.2 InChI
InChI=1S/C12H19N3O.ClH/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3;/h4-7,9,13-14H,8H2,1-3H3,(H,15,16);1H
2.1.3 InChI Key
DERJYEZSLHIUKF-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)NC(=O)C1=CC=C(C=C1)CNNC.Cl
2.2 Other Identifiers
2.2.1 UNII
XH0NPH5ZX8
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Hydrochloride, Procarbazine

2. Matulane

3. Monohydrobromide, Procarbazine

4. Monohydrochloride, Procarbazine

5. Natulan

6. Procarbazine

7. Procarbazine Monohydrobromide

8. Procarbazine Monohydrochloride

2.3.2 Depositor-Supplied Synonyms

1. 366-70-1

2. Procarbazine Hcl

3. Matulane

4. Nathulane

5. Natunalar

6. Natulan

7. Ibenzmethyzine Hydrochloride

8. Procarbazine.hcl

9. Mih Hydrochloride

10. Pcb Hydrochloride

11. Procarbazine (hydrochloride)

12. Nsc-77213

13. Nci-c01810

14. N-isopropyl-4-((2-methylhydrazinyl)methyl)benzamide Hydrochloride

15. Ro 4-6467/1

16. Chebi:71428

17. Xh0nph5zx8

18. P-(n'-methylhydrazinomethyl)-n-isopropylbenzamide Hydrochloride

19. 366-70-1 (hcl)

20. Nsc-77213 Hcl

21. Mbh

22. 1-(p-isopropylcarbamoylbenzyl)-2-methylhydrazine Hydrochloride

23. 1-methyl-2-(p-isopropylcarbamoylbenzyl)hydrazine Hydrochloride

24. 1-methyl-2-p-(isopropylcarbamoyl)benzohydrazine Hydrochloride

25. N-isopropyl-p-(2-methylhydrazinomethyl)benzamide Hydrochloride

26. Nsc 77213

27. 2-(p-(isopropylcarbamoyl)benzyl)-1-methylhydrazine Hydrochloride

28. N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide Hydrochloride

29. Ro-4-6467 Hydrochloride

30. Nsc77213

31. Nci-c 01810

32. Nci-c-01810

33. Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-, Monohydrochloride

34. Procarbazine Hydrochloride (matulane)

35. Ro-46467/1

36. Ro 4 6467/1

37. 4-[(2-methylhydrazinyl)methyl]-n-propan-2-ylbenzamide;hydrochloride

38. Dsstox_cid_1190

39. N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]benzamide Hydrochloride

40. Dsstox_rid_76000

41. Dsstox_gsid_21190

42. Natulan Hydrochloride

43. Procarbazine Chloridrate

44. Ibenzmethyzin Hydrochloride

45. 4-[(2-methylhydrazin-1-yl)methyl]-n-(propan-2-yl)benzamide Hydrochloride

46. Ccris 531

47. Ncgc00016438-01

48. Ro-4646711

49. Cas-366-70-1

50. Ibz

51. Ro-4-6467/1

52. Einecs 206-678-6

53. Unii-xh0nph5zx8

54. Ai3-50844

55. Sr-01000763375

56. Matulane (tn)

57. Mfcd00072082

58. N-isopropyl-4-[(2-methylhydrazino)methyl]benzamide Hydrochloride

59. Procarbazine Hydrochloride [usan:usp:jan]

60. N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide Monohydrochloride

61. P-toluamide, N-isopropyl-alpha-(2-methylhydrazino)-, Hydrochloride

62. Procarbazini Hydrochloridum

63. Chlorhydrate De 1-methyl 2 P (isopropylcarbamoyl)benzyl-hydrazine [french]

64. Schembl4012

65. Methyl)benzamide Hydrochloride

66. Procarbazine Monohydrochloride

67. Mls001401414

68. P-toluamide, Monohydrochloride

69. Chembl1200410

70. Dtxsid3021190

71. Amy8865

72. Hms1571o06

73. Bcp02880

74. Chlorhydrate De 1-methyl 2 P (isopropylcarbamoyl)benzyl-hydrazine

75. Procarbazine Hydrochloride (natulan)

76. Tox21_110439

77. Tox21_302318

78. Bdbm50247906

79. P-toluamide, N-isopropyl-alpha-(2-methylhydrazino)-, Monohydrochloride

80. S1995

81. Wln: 1y1&mvr D1mm1 &gh

82. N-isopropyl-4-((2-methylhydrazinyl)

83. Akos015895395

84. Tox21_110439_1

85. Ccg-100985

86. Nc00235

87. Procarbazine Hydrochloride (jp17/usp)

88. Procarbazine Hydrochloride [mi]

89. Procarbazine Hydrochloride [jan]

90. Ncgc00016438-04

91. Ncgc00255389-01

92. Procarbazine Hydrochloride [iarc]

93. Procarbazine Hydrochloride [usan]

94. Ac-12163

95. As-13285

96. Bp164298

97. Hy-13733

98. Procarbazine Hydrochloride [mart.]

99. Procarbazine Hydrochloride [vandf]

100. Ro 4-646711

101. Smr000469151

102. Bcp0726000264

103. Procarbazine Hydrochloride [usp-rs]

104. Procarbazine Hydrochloride [who-dd]

105. Procarbazine Hydrochloride [who-ip]

106. Db-048987

107. Procarbazine Hydrochloride, >=98% (hplc)

108. Ft-0603386

109. P2550

110. C07376

111. D00478

112. Procarbazine Hydrochloride [orange Book]

113. 366p701

114. A823326

115. Procarbazine Hydrochloride [usp Monograph]

116. Procarbazini Hydrochloridum [who-ip Latin]

117. Sr-01000763375-4

118. Q26840941

119. Z1550675463

120. 4-[(methylhydrazo)methyl]-n-propan-2-ylbenzamide Hydrochloride

121. Methyl-[[4-(propan-2-ylcarbamoyl)phenyl]methylamino]azanium;chloride

122. N-isopropyl-4-((2-methylhydrazinyl)methyl)benzamidehydrochloride

123. 4-[(2-methyl-hydrazino)-methyl]-benzoic Acid Isopropylamide Hydrochloride

124. 4-[(2-methylhydrazinyl)methyl]-n-propan-2-yl-benzamide Hydrochloride

125. N-isopropyl-.alpha.-(2-methylhydrazino)-p-toluamide Monohydrochloride

126. Procarbazine Hydrochloride, United States Pharmacopeia (usp) Reference Standard

2.4 Create Date
2005-08-01
3 Chemical and Physical Properties
Molecular Weight 257.76 g/mol
Molecular Formula C12H20ClN3O
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count3
Rotatable Bond Count5
Exact Mass257.1294900 g/mol
Monoisotopic Mass257.1294900 g/mol
Topological Polar Surface Area53.2 Ų
Heavy Atom Count17
Formal Charge0
Complexity210
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameMatulane
PubMed HealthProcarbazine (By mouth)
Drug ClassesAntineoplastic Agent
Drug LabelMatulane (procarbazine hydrochloride), a hydrazine derivative antineoplastic agent, is available as capsules containing the equivalent of 50 mg procarbazine as the hydrochloride. Each capsule also contains cornstarch, mannitol and talc. Gelatin capsu...
Active IngredientProcarbazine hydrochloride
Dosage FormCapsule
RouteOral
Strengtheq 50mg base
Market StatusPrescription
CompanySigma Tau

2 of 2  
Drug NameMatulane
PubMed HealthProcarbazine (By mouth)
Drug ClassesAntineoplastic Agent
Drug LabelMatulane (procarbazine hydrochloride), a hydrazine derivative antineoplastic agent, is available as capsules containing the equivalent of 50 mg procarbazine as the hydrochloride. Each capsule also contains cornstarch, mannitol and talc. Gelatin capsu...
Active IngredientProcarbazine hydrochloride
Dosage FormCapsule
RouteOral
Strengtheq 50mg base
Market StatusPrescription
CompanySigma Tau

5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Alkylating Drug [EPC]; Alkylating Activity [MoA]

Drugs in Development

read-more
read-more

Details:

Rituximab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lymphoma.


Lead Product(s): Rituximab,Methotrexate,Procarbazine Hydrochloride,Temozolomide,Lisocabtagene Maraleucel,Fludarabine Phosphate,Cyclophosphamide,Calcium Folinate

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Antibody, Unconjugated

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 11, 2025

blank

01

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Rituximab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lymphoma.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

June 11, 2025

blank

Details:

ONO-4059 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Central Nervous System Lymphoma.


Lead Product(s): ONO-4059,Rituximab,Methotrexate,Procarbazine Hydrochloride,Vincristine Sulfate

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 07, 2024

blank

02

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : ONO-4059 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Central Nervous System Lymphoma.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 07, 2024

blank

03

Merck & Co

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Merck & Co

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Details : Pembrolizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hodgkin Disease.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

August 17, 2021

blank
  • Development Update

Details:

Rituximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Central Nervous System Lymphoma.


Lead Product(s): Rituximab,Methotrexate,Procarbazine Hydrochloride,Lenalidomide

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Antibody, Unconjugated

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 12, 2018

blank

04

International Extranodal Lymphoma Study Group

Country
arrow
PEGS Boston Summit
Not Confirmed

International Extranodal Lymphoma Study Group

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Rituximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Central Nervous System Lymphoma.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

April 12, 2018

blank

Details:

Natulan is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Hodgkin Disease.


Lead Product(s): Procarbazine Hydrochloride,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 15, 2016

blank

05

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Natulan is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Hodgkin Disease.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 15, 2016

blank
  • Development Update

Details:

Lomustine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.


Lead Product(s): Lomustine,Etoposide,Cyclophosphamide,Procarbazine Hydrochloride

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: National Cancer Institute | The Emmes Company, LLC | University of Arkansas

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 25, 2013

blank

06

AIDS Malignancy Consortium

Country
arrow
PEGS Boston Summit
Not Confirmed

AIDS Malignancy Consortium

Country
arrow
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Lomustine,Etoposide,Cyclophosphamide,Procarbazine Hydrochloride

Therapeutic Area : Oncology

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : National Cancer Institute | The Emmes Company, LLC | University of Arkansas

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Lomustine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 25, 2013

blank
  • Development Update

Details:

Rituximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.


Lead Product(s): Rituximab,Cytarabine,Methotrexate,Procarbazine Hydrochloride,Vincristine Sulfate

Therapeutic Area: Pharmacology/Toxicology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Antibody, Unconjugated

Sponsor: National Cancer Institute | NRG Oncology

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 21, 2011

blank

07

Radiation Therapy Oncology Group

Country
arrow
PEGS Boston Summit
Not Confirmed

Radiation Therapy Oncology Group

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Rituximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

July 21, 2011

blank
  • Development Update

Details:

Doxorubicin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.


Lead Product(s): Doxorubicin Hydrochloride,Bleomycin Sulphate,Vinblastine Sulfate,PET,Dacarbazine,Etoposide,Cyclophosphamide,Vincristine Sulfate,

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Cytotoxic Drug

Sponsor: National Cancer Institute

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 11, 2011

blank

08

ECOG-ACRIN Cancer Research Group

Country
arrow
PEGS Boston Summit
Not Confirmed

ECOG-ACRIN Cancer Research Group

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Doxorubicin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.

Product Name : Undisclosed

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

July 11, 2011

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Direct Compression

read-more
read-more

Taste Masking

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Empty Capsules

read-more
read-more

Co-Processed Excipients

read-more
read-more

Parenteral

read-more
read-more

Granulation

read-more
read-more

Coating Systems & Additives

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Solubilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Looking for 366-70-1 / Procarbazine Hydrochloride API manufacturers, exporters & distributors?

Procarbazine Hydrochloride manufacturers, exporters & distributors 1

96

PharmaCompass offers a list of Procarbazine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Procarbazine Hydrochloride manufacturer or Procarbazine Hydrochloride supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Procarbazine Hydrochloride manufacturer or Procarbazine Hydrochloride supplier.

API | Excipient name

Procarbazine Hydrochloride

Synonyms

366-70-1, Procarbazine hcl, Matulane, Nathulane, Natunalar, Natulan

Cas Number

366-70-1

Unique Ingredient Identifier (UNII)

XH0NPH5ZX8

About Procarbazine Hydrochloride

An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.

Procarbazine Hydrochloride Manufacturers

A Procarbazine Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Procarbazine Hydrochloride, including repackagers and relabelers. The FDA regulates Procarbazine Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Procarbazine Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Procarbazine Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Procarbazine Hydrochloride Suppliers

A Procarbazine Hydrochloride supplier is an individual or a company that provides Procarbazine Hydrochloride active pharmaceutical ingredient (API) or Procarbazine Hydrochloride finished formulations upon request. The Procarbazine Hydrochloride suppliers may include Procarbazine Hydrochloride API manufacturers, exporters, distributors and traders.

click here to find a list of Procarbazine Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Procarbazine Hydrochloride USDMF

A Procarbazine Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Procarbazine Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Procarbazine Hydrochloride DMFs exist exist since differing nations have different regulations, such as Procarbazine Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Procarbazine Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Procarbazine Hydrochloride USDMF includes data on Procarbazine Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Procarbazine Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Procarbazine Hydrochloride suppliers with USDMF on PharmaCompass.

Procarbazine Hydrochloride NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Procarbazine Hydrochloride as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Procarbazine Hydrochloride API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Procarbazine Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Procarbazine Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Procarbazine Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Procarbazine Hydrochloride suppliers with NDC on PharmaCompass.

Procarbazine Hydrochloride GMP

Procarbazine Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Procarbazine Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Procarbazine Hydrochloride GMP manufacturer or Procarbazine Hydrochloride GMP API supplier for your needs.

Procarbazine Hydrochloride CoA

A Procarbazine Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Procarbazine Hydrochloride's compliance with Procarbazine Hydrochloride specifications and serves as a tool for batch-level quality control.

Procarbazine Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Procarbazine Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Procarbazine Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Procarbazine Hydrochloride EP), Procarbazine Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Procarbazine Hydrochloride USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty